After Russia claiming that it has developed the world’s first covid vaccine offering “sustainable immunity” against covid-19. An committee headed by NITI Aayog will meet today to consider the aspects of getting and administering the vaccine.
While Russia has launched the vaccine, the clinical trials were not yet complete.
In India, the VK Paul committee on vaccine administration will engage with all stakeholders including state governments and vaccine manufacturers and its terms of reference include selecting suitable vaccines, their procurement and delivery and prioritising groups to administer them.
“It also will check out aspects associated with logistics like cold chain and inventory, arrangement of resources for procuring the vaccine and problems with equity. This expert group will continue its engagement with all state governments and vaccine manufacturers in India,” said Health Ministry Secretary Rajesh Bhushan at a press briefing on Tuesday.
Three vaccine candidates are in several stages of human clinical trials in India.
The phase-1 and a couple of human clinical trials of two of them, developed indigenously by Bharat Biotech, together with the Indian Council of Medical Research, and Zydus Cadila Ltd, are happening .
The Serum Institute of India has been permitted for conducting Phase 2 and three human clinical trials of the third vaccine candidate developed by the Oxford University . The Pune-based institute has partnered with AstraZeneca for manufacturing it.
The Oxford vaccine is additionally undergoing final-phase-3 trial in Brazil.
The Serum Institute has said it’s entered into a replacement partnership with international vaccine alliance Gavi and Bill and Melinda Gates Foundation to accelerate manufacturing and delivery of up to 100 million doses of vaccines for India and other low and middle-income countries